We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$6.46B
AUM Growth
-$2.68M
Cap. Flow
-$106M
Cap. Flow %
-1.64%
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17

Top Buys

Rank Stock Value
1
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
+$201M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$91.6M
3
QURE icon
uniQure
QURE
+$57.2M
4
NTRA icon
Natera
NTRA
+$47.4M
5
ATNX
Athenex, Inc. Common Stock
ATNX
+$47.3M

Top Sells

Rank Stock Value
1
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$272M
2
GH icon
Guardant Health
GH
+$118M
3
VTRS icon
Viatris
VTRS
+$77.1M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$64M
5
HUM icon
Humana
HUM
+$55.9M

Sector Composition

Rank Sector Weight
1 Healthcare 95.58%
2 Financials 1.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HARP
51
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$31.8M 0.49%
244,641
– –
CDNA icon
52
CareDx
CDNA
$1.85B
$29.8M 0.46%
827,600
– –
OBSV
53
DELISTED
ObsEva SA Ordinary Shares
OBSV
$29.5M 0.46%
2,605,531
– –
SPY icon
54
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$779B
$29.3M 0.45%
100,000
+50,000
+100% +$14.4M
CLVS
55
DELISTED
Clovis Oncology, Inc.
CLVS
$28.4M 0.44%
1,913,234
-919,066
-32% -$16.6M
XTNT icon
56
Xtant Medical Holdings
XTNT
$57.7M
$27.6M 0.43%
9,207,012
– –
GILD icon
57
Gilead Sciences
GILD
$166B
$27.1M 0.42%
401,600
-42,200
-10% -$2.78M
VTRS icon
58
Viatris
VTRS
$20.9B
$26.1M 0.41%
1,373,305
-3,488,495
-72% -$77.1M
KRYS icon
59
Krystal Biotech
KRYS
$10.7B
$25.9M 0.4%
642,006
+582,796
+984% +$19.1M
ENDP
60
DELISTED
Endo International plc
ENDP
$25.4M 0.39%
6,165,464
– –
CRVS icon
61
Corvus Pharmaceuticals
CRVS
$1.12B
$24.6M 0.38%
6,565,685
+598,101
+10% +$2.34M
ADVM
62
DELISTED
Adverum Biotechnologies
ADVM
$23.3M 0.36%
196,020
+71,700
+58% +$5.93M
AUPH icon
63
Aurinia Pharmaceuticals
AUPH
$1.93B
$23.2M 0.36%
3,531,002
+381,192
+12% +$2.43M
BMY icon
64
CALL
Bristol-Myers Squibb
BMY
$130B
$22.7M 0.35%
+500,000
New +$23.3M
ONCE
65
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$22.5M 0.35%
+219,900
New +$23.7M
AMGN icon
66
Amgen
AMGN
$213B
$22.5M 0.35%
122,100
– –
GNFT
67
DELISTED
Genfit
GNFT
$22.2M 0.34%
1,125,607
-104,707
-9% -$2.45M
KALA icon
68
KALA BIO
KALA
$12.1M
$22M 0.34%
1,381
– –
ALC icon
69
Alcon
ALC
$34B
$21.7M 0.34%
+351,380
New +$20.6M
BIIB icon
70
Biogen
BIIB
$31.9B
$20.5M 0.32%
87,700
– –
SIBN icon
71
SI-BONE Inc
SIBN
$801M
$20M 0.31%
985,368
– –
KPTI icon
72
Karyopharm Therapeutics
KPTI
$157M
$18.9M 0.29%
+209,898
New +$16.9M
SYBX
73
DELISTED
Synlogic
SYBX
$18.5M 0.29%
135,333
– –
TAK icon
74
CALL
Takeda Pharmaceutical
TAK
$56.6B
$17.7M 0.27%
1,000,000
– –
RYTM icon
75
Rhythm Pharmaceuticals
RYTM
$7.4B
$17.3M 0.27%
787,300
– –
1 2
3
4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2019 Portfolio in Review

As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Financials.

  • OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
  • OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
  • OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
  • OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
  • OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
  • OrbiMed opened 22 new positions and closed 17 in Q2 2019.
  • OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.

Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.